Table 1.
Patient and treatment characteristics
| Characteristic | No. (%) or Median [range] |
|---|---|
| No. of patients | 35 |
| Age, years | 66 [45-85] |
| Sex, male | 21 (60) |
| Karnofsky performance status score ≥80% | 28 (80) |
| Baseline eGFR, mL/min/1.73 m2 | 78.9 ± 19.2a |
| Metastasis origin: | |
| Non-small cell lung cancer | 17 (48) |
| Hepatocellular carcinoma | 7 (20) |
| Gastrointestinal tract | 3 (9) |
| Renal cell carcinoma | 2 (6) |
| Other | 6 (17) |
| Primary tumor histology: | |
| Adenocarcinoma | 18 (51) |
| Hepatocellular carcinoma | 7 (20) |
| Squamous cell carcinoma | 4 (12) |
| Other | 6 (17) |
| Controlled/absent primary, yes | 20 (57) |
| Other sites of metastases: | |
| None | 10 (29) |
| 1 site | 11 (31) |
| >1 site | 14 (40) |
| Adrenal tumor diagnosis: | |
| Synchronous | 7 (20) |
| Metachronous | 28 (80) |
| Adrenal metastases location: | |
| Left | 17 (48) |
| Right | 14 (40) |
| Bilateral | 4 (12) |
| Adrenal metastases size, cm: | 2.9 [0.7-9] |
| Prior local therapy, yes | 3 (8) |
| Prior radiation therapy to abdomen, yes | 9 (26) |
| Stereotactic body radiation therapy treatment: | |
| Total dose, Gy | 40 [20-54] |
| No. of fractions | 5 [1-6] |
| Total BED10, Gy | 72 [30-124.8] |
| Planning technique: | |
| Volumetric modulated arc therapy | 35 (90) |
| Intensity modulated radiation therapy | 4 (10) |
| Implanted fiducials, yes | 16 (41) |
| Gross tumor volume, cm3 | 19 [1.3-213.2] |
| Planning target volume, cm3 | 50.5 [7.9-352.9] |
| Mean dose, Gy | 42.3 [21.4-57.3] |
| Maximum dose, Gy | 46.5 [23.3-61.9] |
| Minimum dose, Gy | 31.2 [17.3-47.3] |
| Conformity index | 1 [0.9-1.2] |
| R50% | 4 [3.1-9.1] |
| Homogeneity, % | 116 [103-133] |
eGFR, estimated glomerular filtration rate; BED10, biologically effective dose calculated with a α/β of 10; R50%, ratio of the 50% prescription isodose volume to PTV volume.
a
Mean ± standard deviation.